Clinical Trial Update: Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of suberoylanilide hydroxamic acid (vorinostat) for progressive Stage IV breast cancer was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-03-19